GlassScriptPhysician profile
Thavatchai Chamnongchareonwong
NPI 1023038353
$17,899.51
in general payments reported to CMS, 2019-2025
48 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,790 · 2020: $2,959 · 2021: $3,449 · 2022: $2,244 · 2023: $2,553 · 2024: $2,173 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,247 · Education: $184 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,246.77 |
| Education | $184.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $2,244.63 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Astrazeneca Pharmaceuticals LP | $2,053.00 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Amarin Pharma, INC. | $1,578.23 | 2019-2023 | |
| Novo Nordisk INC | $1,275.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,263.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,176.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,101.61 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $919.00 | 2019-2025 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $673.51 | 2019-2021 | |
| Esperion Therapeutics, INC. | $662.60 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $528.18 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $336.91 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.39 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $332.93 | 2019-2021 | |
| Pfizer INC. | $324.05 | 2019-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thavatchai Chamnongchareonwong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.